Jazz, With New Patent, Expands Fight on Avadel’s Narcolepsy Drug

Jazz Pharmaceuticals expanded its courtroom battle seeking to block sales of Avadel’s proposed once-nightly narcolepsy drug, which Jazz said infringes a patent issued Tuesday related to its drug Xyrem.

• Jazz is seeking court order blocking Avadel from making or selling its product, a branded drug currently known as FT218, and cash compensation if it does so before patent has expired, according to complaint filed Wednesday in federal court in Wilmington, Delaware
• Patent was issued Tuesday and covers methods of use and administration of drug compositions containing sodium oxybate, the active ingredient in Jazz’s twice-nightly Xyrem
  • Patent covers formulation of, ...